Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.97 -0.10 (-0.65%)

Streaming Delayed Price Updated: 10:03 AM EST, Jan 22, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Time to buy these 3 healthcare companies that raised revenue guidance?

January 16, 2024

The new year brings a clean slate heading into the fourth-quarter earnings season. Check out a few companies that have raised revenue guidance.

Via MarketBeat

U.S. FDA Approves Takeda’s HYQVIA® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

January 16, 2024

From Takeda Pharmaceutical Company Limited

Via Business Wire

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

January 15, 2024

Via Benzinga

Week In Review: China Biopharmas Book $9 Billion In Deals During JP Morgan Conference Week ↗

January 13, 2024

Shanghai Argo Biopharma entered 2 agreements with Novartis, out-licensing four next-gen RNAi therapeutics for $185 million upfront and a total value of $4.2 billion. Additionally, Ambrx Biopharma will...

Via Talk Markets

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

December 25, 2023

Via Benzinga

(TAK) - Analyzing Takeda Pharmaceutical's Short Interest ↗

December 07, 2023

Via Benzinga

Peering Into Takeda Pharmaceutical's Recent Short Interest ↗

November 21, 2023

Via Benzinga

More Than 140 Drug Brands Will Have Their Prices Hiked Heading Into 2024 ↗

January 04, 2024

More than 140 brands of drugs are going to see their prices hiked heading into the new year

Via Talk Markets

Expensive Drugs For Americans In 2024? Drugmakers Including Pfizer, Sanofi Mull Price Increase In January ↗

December 29, 2023

Just as large pharma companies prepare a showdown with Medicare's newfound power to negotiate down drug prices, several major drug companies are reportedly gearing up to implement price increases on...

Via Benzinga

One Ultra-Cheap High-Yield Dividend Stock to Buy ↗

December 22, 2023

Now may be a good time for dividend investors to consider loading up on this stock.

Via The Motley Fool

Takeda Announces China NMPA Approval of LIVTENCITY® (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Refractory to Prior Therapies

December 21, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

November 03, 2023

Via Benzinga

A Look Into Takeda Pharmaceutical Inc's Price Over Earnings ↗

October 19, 2023

Via Benzinga

Ionis' Strategic Shift Praised by Analysts For Donidalorsen's Global Reach ↗

December 19, 2023

Monday, Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered into a license agreement with Otsuka Pharmaceutical Co Ltd under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen,...

Via Benzinga

Takeda Receives Positive CHMP Opinion for HYQVIA® as Maintenance Therapy in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

December 15, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and The New York Academy of Sciences Announce 2024 Innovators in Science Award Winners

December 05, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda to Present Data at 65th American Society of Hematology (ASH) Annual Meeting, Demonstrating Continued Commitment to Patients with Hematologic Diseases

November 27, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Why Is Neurocrine Biosciences Stock Trading Lower Today? ↗

November 10, 2023

Thursday, Neurocrine Biosciences Inc (NASDAQ: NBIX)

Via Benzinga

Back To Back FDA Approval For Takeda Within Two Days, Secures Green Signal For Rare Blood Disorder Therapy ↗

November 10, 2023

The FDA approved Takeda Pharmaceutical Co Ltd's (NYSE:

Via Benzinga

Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)

November 09, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer

November 08, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

3 Promising Biotech Stocks Flying Under the Radar ↗

November 08, 2023

Breakthroughs in healthcare are happening everyday, make sure you are keeping up to date on these under the radar biotech stocks.

Via InvestorPlace

Takeda Announces Late-Breaking Data from Phase 2b Study of TAK-279, an Investigational, Oral, Once-Daily TYK2 Inhibitor, in Patients with Active Psoriatic Arthritis at American College of Rheumatology Convergence Annual Meeting

November 07, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Earnings Scheduled For October 26, 2023 ↗

October 26, 2023

Companies Reporting Before The Bell • TotalEnergies (NYSE:TTE) is likely to report quarterly earnings at $2.57 per share on revenue of $49.83 billion.

Via Benzinga

Takeda Announces FY2023 H1 Results; Updates Full-Year Forecasts While Remaining on Track Towards Management Guidance

October 26, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone. ↗

October 23, 2023

Analysts say Alkermes' drug is clearly active. But investors have concerns.

Via Investor's Business Daily

Week In Review: China's Biopharmas Announce $2.5 Billion In Deals ↗

October 21, 2023

KBP Biosciences sold global rights for its hypertension candidate to Novo Nordisk in an agreement worth up to $1.3 billion. Also, EpimAb Bio sold the rights to use its Fabs-In-Tandem Immunoglobulin...

Via Talk Markets

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Previously Untreated CD30+ Stage III Hodgkin Lymphoma in Combination with AVD

October 18, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda's Crohn's Disease Fistulas Candidates Fall Short In Mid-Stage Study, Settles Tax Dispute With Irish Revenue Commissioners ↗

October 18, 2023

Takeda Pharmaceutical Co Ltd (NYSE: TAK) released topline data from the Phase 3 ADMIRE-CD II study, assessing Alofisel (darvadstrocel) for complex Crohn's Perianal Fistulas (CPF).

Via Benzinga

Takeda Settles Tax Dispute with Irish Revenue over Break Fee Received by Shire

October 17, 2023

From Takeda Pharmaceutical Company Limited

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.